Plants as an innovative and accelerated vaccine-manufacturing solution: A plant-based expression system could provide greater speed and capacity than other recombinant technologies at a comparatively low cost

BioPharm International

Volumn 24, Issue MAY SUPPL., 2011, Pages

  Vézina, Louis P ^a   D'Aoust, Marc André ^a   Landry, Nathalie ^a   Couture, Manon M J ^a   Charland, Nathalie ^a   Ors, Frédéric ^a   Barbeau, Brigitte ^a   Sheldon, Andy J ^a  

^a Medicago Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIGEN;

ARTICLE; BIOMASS PRODUCTION; CHROMATOGRAPHY; DRUG IMPURITY; DRUG MANUFACTURE; DRUG SYNTHESIS; GENE EXPRESSION SYSTEM; GENE SEQUENCE; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INOCULATION; MEDICAGO; NONHUMAN; PLANT BIOTECHNOLOGY; PLASMID; RHIZOBIUM; VACCINE PRODUCTION; VIRUS LIKE AGENT;

EID: 79957868491     PISSN: 1542166X     EISSN: 19391862     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (5)

1. O. Wyman and the Program for Appropriate Technology in Health, "Influenza Vaccine Strategies for Broad Global Access," (PATH, Washington, DC, 2007).
2. M.A. D'Aoust et al., Plant Biotechnol. J. 6 (9), 930-940 (2008).
3. N. Landry, PLoS ONE 5 (12), e15559 (2010).
4. E.V.L. Grgacic and D.A. Anderson, Methods 40 (1), 60-65 (2006).
5. President's Council of Advisors on Science and Technology, "Report to the President on Reengineering the Influenza Vaccine Production Enterprise to Meet the Challenges of Pandemic Influenza" (Washington, DC, August 2010).